Kiniksa Pharmaceuticals International stock
KNSANASDAQKiniksa Pharmaceuticals International, plc, HealthcareISIN GB00BRXB0C07
68Score 68 out of 100, Neutral
Price and trend
87 / 100
Price history
+137% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 54% above it.
Since May 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 65).
The price is 2.5% below its 52-week high. Largest decline in 8 years: 83% (September 2018 to October 2019).
Chart figures for advanced users
- SMA 50$81.86
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$62.57
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)65
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$37.92
- The lowest closing price of the last twelve months.
- Resistance$98.76
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Kiniksa Pharmaceuticals International, plc belongs to the Medical (Pharmaceuticals) industry (United Kingdom) and, with a market value of $7.56B, is number 8 of 15 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $1.05B (up 54.9%) and adjusted earnings per share of $1.48 (up 100.6%).
- MEQIRI Score 68 out of 100 (Neutral): rank 163 of 702 in Healthcare, median 53.
Show more
- The P/E is 74.6 (Medical (Pharmaceuticals) median 35.7, own median of recent years 51.6).
- Our model puts fair value at $93.19, with the price 3% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 31.9% a year through 2028 (estimates from 6 analysts).Growth 50
- More cash than debtCash $568.76M, financial debt $7.88M.Stability 82
- High return on capitalReturn on invested capital 27.9% in fiscal 2025, Medical (Pharmaceuticals) median 6.7%.Profitability 79
Weaknesses
- Richly valuedP/E 74.6, Medical (Pharmaceuticals) median 35.7, own median 51.6.Valuation 32
- DilutionShare count up 20% since 2020.Capital allocation 54
- Volatile share priceVolatility 56% a year over the last 12 months.
Its standout strengths are momentum and technical analysis, while valuation holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $66.57 and expensive above $155.32 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $140.32 (cash-flow model) and $46.06 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9%. At 10% the fair value would be $80.13, at 8% it would be $112.70.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (35.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 58.2% on the twelve months before. Revenue turned from negative at the start of the period to positive ($677.56M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 55%, operating 11%, net 9%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 23 Feb 2027in 102 days
- Last reported
- 27 Oct 2026EPS reported $0.56 (expected $0.37)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 6.6% since 15 Oct 2026.
- Earnings per share
- $1.48+6.6%
- Revenue
- $1.05B+5.6%
- Earnings per share
- $2.03−1.3%
- Revenue
- $1.32B+8.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +30.4%Kiniksa raised its 2026 ARCALYST revenue guidance to between $1.045 billion and $1.050 billion and now expects the drug to exceed $1 billion in sales for the first time.
“Looking ahead, in addition to our updated 2026 ARCALYST sales guidance of $1.045 billion-$1.050 billion, we are providing full year R&D and SG&A expense guidance. We expect full year R&D expenses of $160 million-$170 million in 2026.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 27 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $78.89M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Megna Michael RSale
9 Nov 2026, CHIEF ACCOUNTING OFFICER
- Shares
- 11,280
- Price
- $98.54
- Value
- $1.11M
- Patel Sanj KSale
4 Nov 2026, CHAIRMAN & CEO
- Shares
- 151,300
- Price
- $94.71
- Value
- $14.33M
- Patel Sanj KSale
3 Nov 2026, CHAIRMAN & CEO
- Shares
- 220,170
- Price
- $93.27
- Value
- $20.54M
Show 10 more
- Patel Sanj KSale
2 Nov 2026, CHAIRMAN & CEO
- Shares
- 89,433
- Price
- $91.86
- Value
- $8.22M
- Ragosa MarkSale
2 Nov 2026, CHIEF FINANCIAL OFFICER
- Shares
- 36,783
- Price
- $92.16
- Value
- $3.39M
- Paolini John F.Sale
2 Nov 2026, CHIEF MEDICAL OFFICER
- Shares
- 18,413
- Price
- $93.39
- Value
- $1.72M
- Moat RossSale
2 Nov 2026, CHIEF OPERATING OFFICER
- Shares
- 27,977
- Price
- $92.36
- Value
- $2.58M
- Patel Sanj KSale
30 Oct 2026, CHAIRMAN & CEO
- Shares
- 92,891
- Price
- $93.12
- Value
- $8.65M
- Paolini John F.Sale
30 Oct 2026, CHIEF MEDICAL OFFICER
- Shares
- 77,587
- Price
- $93.02
- Value
- $7.22M
- Moat RossSale
30 Oct 2026, CHIEF OPERATING OFFICER
- Shares
- 75,608
- Price
- $93.13
- Value
- $7.04M
- Megna Michael RSale
30 Oct 2026, CHIEF ACCOUNTING OFFICER
- Shares
- 36,260
- Price
- $94.43
- Value
- $3.42M
- Megna Michael RSale
3 Sept 2026, CHIEF ACCOUNTING OFFICER
- Shares
- 4,600
- Price
- $80.30
- Value
- $369,380
- Cole G BradleySale
29 Jul 2026, Board
- Shares
- 3,673
- Price
- $81.43
- Value
- $299,092
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Kiniksa Pharmaceuticals International
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 68
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Pharmaceuticals)
The next larger and next smaller companies by market value
- Sino Biopharmaceutical1177.HK $12.58B65
- Recordati Industria Chimica e FarmaceuticaREC.MI $11.92B74
- Kyowa Kirin4151.T $8.4B77
- Corcept TherapeuticsCORT $8.07B75
- Tsuruha Holdings3391.T $7.1B62
- MatsukiyoCocokara3088.T $6.71B75
- Abbott IndiaABBOTINDIA.NS $6.01B75
- LiquidiaLQDA $5.24B43
ETFs that hold Kiniksa Pharmaceuticals International
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.40% | 0.40% | €1.5B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.28% | 0.35% | €1.25B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.20% | 0.30% | €185.82M |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.15% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.15% | 0.30% | €4.28B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.12% | 0.43% | €2.5B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.04% | 0.10% | €395.74M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.03% | 0.45% | €1.54B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Oct 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.